Incidence and case-fatality rate of neonatal sepsis remain high in developing countries. This article reviews developments in the areas of neutrophil transfusions, granulocyte stimulation factors (G-CSF and GM-CSF), intravenous immune-globulin and certain developments in our understanding of the systemic inflammatory inflammatory response syndrome (SIRS). Currently none of these therapies have proven the early promise foreseen in them. Thus, these therapies still remain experimental in the treatment of neonatal sepsis.
immunoglobulins, G-CSF, granulocytes
